Application of Serum Bile Acid Profile in the Diagnosis of Gastric Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06031779

Enrollment

1000

Registered

2023-09-11

Start date

2023-05-01

Completion date

2024-07-01

Last updated

2025-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Keywords

serum bile acid, biomarker

Brief summary

In this study, the composition and level of serum bile acids in patients with gastric cancer and non-gastric cancer were analyzed by detecting the serum bile acid profile, so as to develop new serological diagnostic methods for early diagnosis and treatment of gastric cancer.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Inclusion criteria

1. Age between 18-70, both gender; 2. The gastric cancer group was early gastric cancer or advanced gastric cancer diagnosed by endoscopic examination and pathological biopsy. The non-gastric cancer group included patients without gastric lesions, superficial gastritis, chronic atrophic gastritis, intestinal metaplasia or dysplasia diagnosed by gastroscopy or pathological biopsy; 3. Informed consent was obtained.

Exclusion criteria

1. The patients have diseases that affect bile acid metabolism, such as liver cirrhosis, gallstones or inflammatory bowel disease, Behcet's disease, etc; 2. Due to other diseases, the patient took drugs affecting bile acid metabolism, such as cholestyramine, anti-inflammatory Lidan tablets, Danshu capsules, ursodeoxycholic acid, obticholic acid, Schisandrin B, tanshinone ⅡA, Yinzhihuang, etc; 3. Pregnant women; 4. Primary tumors of other systems were diagnosed; 5. Those with poor physiopathological conditions, such as chronic kidney disease requiring long-term dialysis; 6. Patients with mental illness; 7. Patients who have received radiotherapy or surgery previously; 8. Those with poor adherence or difficult to follow up.

Design outcomes

Primary

Measure	Time frame
serum bile acid profile before treatment	1 month

Secondary

Measure	Time frame	Description
concentration of serum tumor markers before treatment	1 month	CEA, CA19-9 and CA12-5

Countries

China

Outcome results